Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 1431985-92-0 Chemical Structure| 1431985-92-0

Structure of K02288
CAS No.: 1431985-92-0

Chemical Structure| 1431985-92-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

K02288 is an inhibitor of type I BMP receptor. It targeting ALK2, ALK1 and ALK6 with IC50 of 1.1, 1.8, 6.4 nM, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of K02288

CAS No. :1431985-92-0
Formula : C20H20N2O4
M.W : 352.38
SMILES Code : OC1=CC=CC(C2=CC(C3=CC(OC)=C(OC)C(OC)=C3)=C(N)N=C2)=C1
MDL No. :MFCD26936347
InChI Key :CJLMANFTWLNAKC-UHFFFAOYSA-N
Pubchem ID :46173038

Safety of K02288

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301-H318
Precautionary Statements:P280-P301+P310-P305+P351+P338
Class:8(6.1)
UN#:2923
Packing Group:

Isoform Comparison

Biological Activity

Target
  • ALK1

    ALK1, IC50:1.8 nM

  • ALK2

    ALK2, IC50:1.1 nM

  • ALK6

    ALK6, IC50:6.4 nM

  • ALK3

    ALK3, IC50:34.4 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Huh7 cells 0.25 µM 5 days Suppressed not only ID1 and EpCAM expression Mol Oncol. 2021 Aug;15(8):2203-2218.
MT cells 0.25 µM 5 days Suppressed not only ID1 and EpCAM expression Mol Oncol. 2021 Aug;15(8):2203-2218.
Huh7 cells 1 µM 24 hours Suppressed the cell invasion/migration ability Mol Oncol. 2021 Aug;15(8):2203-2218.
MT cells 1 µM 24 hours Suppressed the cell invasion/migration ability Mol Oncol. 2021 Aug;15(8):2203-2218.
Lgr5+ CSCs 6.4 nM 3, 5, 7 days K02288 attenuated the radiosensitizing effect of PD on Lgr5+ CSCs, indicating that PD regulates the radiosensitivity of CSCs through the BMP signaling pathway Int J Biol Sci. 2019 Jan 1;15(2):430-440.
Human Umbilical Vein Endothelial Cells (HUVECs) 1 µM 30 minutes K02288 inhibited BMP9-induced phosphorylation of SMAD1/5/8, reducing both the SMAD and Notch-dependent transcriptional responses. Angiogenesis. 2015 Apr;18(2):209-17.
Abdominal preadipocytes 500 nM 30 minutes K02288 completely inhibited BMP2-induced SMAD1/5/8 phosphorylation Int J Obes (Lond). 2019 Dec;43(12):2458-2468.
Gluteal preadipocytes 500 nM 30 minutes K02288 completely inhibited BMP2-induced SMAD1/5/8 phosphorylation Int J Obes (Lond). 2019 Dec;43(12):2458-2468.
C2C12 1 nM to 10 µM 30 minutes Measure inhibition of BMP6-induced transcriptional activity (BRE-Luciferase) J Med Chem. 2014 Oct 9;57(19):7900-15.
HEK293T 1 nM to 10 µM 30 minutes Measure inhibition of TGF-β1-induced transcriptional activity (CAGA-Luciferase) J Med Chem. 2014 Oct 9;57(19):7900-15.
Human Umbilical Vein Endothelial Cells (HUVECs) 1 µM 4 hours K02288 treatment significantly downregulated BMP9 and Notch-dependent target gene expression. Angiogenesis. 2015 Apr;18(2):209-17.
Huh7 cells 0.5 µM 48 hours Suppressed the BMP9-induced upregulation of ID1 and EpCAM expression Mol Oncol. 2021 Aug;15(8):2203-2218.
NGT16 50 µM 72 hours To evaluate the effect of ALK2 inhibitor K02288 on NGT16 cell line, showing approximately 30% reduction in cell viability. Front Oncol. 2020 Jan 21;9:1568.
VSMCs 10 µM K02288 treatment abrogated the effect of TXNIP suppression on osteodifferentiation Circ Res. 2023 Jan 6;132(1):52-71.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Chicken Chick Embryo Chorioallantoic Membrane (CAM) Model Topical Administration 100 µL Single dose, lasting 4 days K02288 caused dysfunctional vessel formation, characterized by hypersprouting and low vessel density. Angiogenesis. 2015 Apr;18(2):209-17.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.84mL

0.57mL

0.28mL

14.19mL

2.84mL

1.42mL

28.38mL

5.68mL

2.84mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories